Microparticles and Bronchiolitis Obliterans Syndrome (MIBO)

University Hospital, Strasbourg, France

Status: Completed

Conditions: Bronchiolitis Obliterans

Treatments: Other: Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)

Study type: Observational

Funder types: Other

Identifiers

NCT02458274

5254 (Other Identifier)

Details and patient eligibility

About

The main long-term complication of lung transplantation is chronic lung allograft dysfunction (CLAD). Bronchiolitis obliterans syndrome (BOS) is the most frequent presentation of CLAD. BOS leads to a progressive loss of lung allograft function, with recurrence of dyspnea and airflow limitation. In some advanced cases, patients need a lung re transplantation. The mechanisms of BOS are not completely elucidated, and there are no early markers or specific treatment available for this condition.

Microparticles (MPs) are submicron plasma membrane fragments released into the vascular compartment or the pericellular space in response to cell activation, injury or apoptosis. Broncho alveolar and circulating MPs may reflect cellular insults of the lung allografts. Therefore, MPs could be viewed either as biomarkers or as effectors of the chronic inflammatory or procoagulant processes leading to bronchiolitis obliterans syndrome.

The investigators plan to include 60 patients before lung transplantation at our centre in Strasbourg (France). Follow-up will be requested at the base of usual care (spirometry, blood sampling, bronchoscopy with broncho-alveolar lavage [BAL]). The investigators will measure at one month, one, two and three year post transplantation, the total concentration of MPs in plasma and BAL and characterize their phenotype.

The investigators objective is to demonstrate correlation between total MPs concentration in broncho-alveolar lavage fluid (BALF) and the occurrence of bronchiolitis obliterans syndrome at three years post lung transplantation.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Every adult (>18 years) patient on lung transplant waiting list
• Patients who give a written informed consent
• Patients affiliated to a social security regimen

Exclusion criteria

• Patients on lung transplant waiting list for BOS
• Patients who cannot sign an informed consent form (emergency situation, patient with understanding difficulties...)

Trial design

60 participants in 2 patient groups

Patient without bronchiolitis obliterans syndrome

Description:

Lung transplanted patient without bronchiolitis obliterans syndrome

Treatment:

Other: Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)

Patient with bronchiolitis obliterans syndrome

Description:

Patient with bronchiolitis obliterans syndrome three years after lung transplantation.

Treatment:

Other: Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)